Pasadena Microenterprise Recovery Grant

The cost of moving can be a significant barrier to relocating for work, often deterring individuals from pursuing new job opportunities. Expenses associated with relocation, such as hiring movers, transportation, temporary housing, and even utility connection fees, can add up quickly. Employers that offer relocation assistance can provide it either in advance or upon arrival, depending on company policies and the nature of the relocation package. Some employers offer upfront assistance, covering expenses like moving services, travel costs, and temporary housing directly, or providing a lump sum payment to help cover costs before the move. This approach is particularly helpful for employees who need financial support to manage the immediate expenses of relocation. Relocation assistance can be a highly effective tool for employers to fill in-demand jobs, especially in industries facing talent shortages. By offering financial support to cover moving expenses, companies can widen their candidate pool to include qualified workers who may otherwise be unable or unwilling to relocate due to the high costs associated with moving. Under this program, Employers can access up to $5,000 of matching funds for each candidate the business is eligible for. A 1:1 match is required. An additional $500 per candidate is available if the applicant is identified in the Find the Good Life Candidate Marketplace. The additional $500 for candidates identified through the Marketplace is not subject to match.

This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

The Disability and Rehabilitation Engineering program is part of the Engineering Biology and Health cluster, which also includes: 1) the Biophotonics program; 2) the Biosensing program; 3) the Cellular and Biochemical Engineering program; and 4) the Engineering of Biomedical Systems program. The Disability and Rehabilitation Engineering program supports fundamental engineering research that will improve the quality of life of persons with disabilities through the development of new theories, methodologies, technologies, or devices. Disabilities could be developmental, cognitive, hearing, mobility, visual, selfcare, independent living, or other. Proposed projects must advance knowledge regarding a specific human disability or pathological motion or understanding of injury mechanisms. Research may be supported that is directed toward the characterization, restoration, rehabilitation, and/or substitution of human functional ability or cognition, or to the interaction between persons with disabilities and their environment. Areas of particular interest are neuroengineering, rehabilitation robotics, brain-inspired assistive or rehabilitative systems, theoretical or computational methods, and novel models of functional recovery including the development and application of artificial physiological systems. Emphasis is placed on significant advancement of fundamental engineering knowledge that facilitates transformative outcomes. The DARE Program encourages high-risk/high-reward proposals that surpass incremental technological improvements. The DARE Program also encourages participatory design and the inclusion of trainees with disabilities as part of the proposed research or broader impacts. Innovative proposals outside of the above specific interest areas may be considered. NSF does not support clinical trials; however, feasibility studies involving human volunteers may be supported if appropriate to the project objectives. The development and application of artificial physiological systems that do not model functional recovery and instead improve fundamental understanding of physiological and pathophysiological processes would be appropriate for EBMS. Furthermore, the DARE program does not support proposals having as their central theme commercialization of a product. Small businesses seeking early stage R&D funding for product development are encouraged to contact the NSF SBIR/STTR program in the America's Seed Fund within the Directorate for Technology, Innovation and Partnerships (TIP).

NAACP, in conjunction with Medium Rare and The Shark Group, has launched applications for the fourth annual NAACP Powershift Entrepreneur Grant in celebration of Black Entrepreneurs Day. The NAACP Powershift Entrepreneur Grant aims to empower Black entrepreneurs and businesses through funding and resources and has, in previous years, contributed largely to the growth of Black businesses across the nation.

The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to identify new druggable targets for pain within the understudied druggable proteome. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s) listed in this NOFO. This NOFO is intended to jumpstart research on understudied proteins within the context of pain and pain management and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins to identify new druggable targets for pain. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.